Angelin B
Metabolism Unit, Huddinge University Hospital, Sweden.
Curr Opin Lipidol. 1997 Dec;8(6):337-41. doi: 10.1097/00041433-199712000-00003.
Elevated levels of lipoprotein (a), a complex between apolipoprotein (a) and LDL, indicate an increased risk of atherosclerosis and cardiovascular disease. The important genetic regulation of lipoprotein (a) is now relatively well understood, but the progress in finding ways of influencing plasma lipoprotein (a) has been disappointingly slow. Nicotinic acid, pharmacological doses of sex hormones and anabolic steroids, as well as LDL apheresis may provide sufficient lowering of lipoprotein (a) for the evaluation of clinical response. Presently, the most important aspect is to take an evaluated lipoprotein (a) level into consideration when deciding to institute particularly aggressive lipid lowering treatment in a given individual.
脂蛋白（a）水平升高，即载脂蛋白（a）与低密度脂蛋白的复合物，表明动脉粥样硬化和心血管疾病风险增加。目前，脂蛋白（a）的重要基因调控机制已相对明确，但在寻找影响血浆脂蛋白（a）的方法方面进展缓慢，令人失望。烟酸、药理剂量的性激素和合成代谢类固醇以及低密度脂蛋白去除法可能会使脂蛋白（a）充分降低，以便评估临床反应。目前，在决定对特定个体实施特别积极的降脂治疗时，最重要的是考虑经过评估的脂蛋白（a）水平。
